The hypolipidaemic properties of the drug clofibrate [Atromid-S, ethyl 2-(4-chlorophenoxy)-2-methylpropionate] in both man and experimental animals are well documented. Despite numerous reports, some conflicting, describing a variety of histological and metabolic changes caused by the drug, its mode of action is still not clear. Investigations using purified liver enzymes, e.g. acetyl-CoA carboxylase (Maragoudakis, 1969) , microsomal fractions (Lamb & Fallon, 1972) , liver slices (Fulton & Hsia, 1972) or isolated hepatocytes (Homcy & Margolis, 1974; Capuzzi et al., 1974) indicate that the drug has immediate and direct actions on the liver. We decided to investigate the direct effects of clofibrate in a more physiological system, the perfused liver.
Three groups of perfusions were carried out. In the first, the perfusate contained 0.75 mM-sodium 2-(4-chlorophenoxy)-2-methylpropionate, the approximate concentration found in the serum of rats fed on the standard dose of the drug (0.25 %, w/w, of the diet). In the second, livers from rats fed on the standard dose of clofibrate for 1 week were perfused, but without addition of the drug to the perfusate. The third group of control perfusions utilized untreated liver donors and drug-free perfusate. A minimum of five perfusions was carried out in each group. Livers from male Wistar rats (340-36Og) were perfused with whole defibrinated rat blood, essentially as described by Mayes & Felts (1966) , but with the following modifications: the perfusions were carried out in situ for an experimental period of 3h with a silicone-rubber gas exchanger.
[l -I4C]Oleate complexed to bovine serum albumin was infused continuously to give a serum free fatty acid concentration of approx. 0.7,umol/ml. Lipogenesis was measured by using 3Hz0 (Mayes & Topping, 1974) . Metabolites determined included blood glucose, ketone bodies, lactate, pyruvate, serum and liver triacylglycerol, serum and liver cholesterol, and serum free fatty acids. The incorporation of [l-14C]oleate into serum and liver lipids, COz and ketone bodies was followed.
Statistical tests between the results from the !%st group of perfusions, in which the drug was added directly, and controls showed no significant differences in any of the parameters measured over the 3 h experimental period. However, many significant differ-563rd MEETING, LONDON ences were found in the perfusions of the livers from pretreated donors. There was a decrease in the mean perfusate serum free fatty acid concentration to O.5pmol/ml (P < O.OOl), and also in the perfusate glucose concentration to 136mg/100ml against a control value of 178mg/100ml (P < 0.001). The treated livers secreted 4.6 f 0.4 (mean f s.E.M.) prnol of triacylglycerol fatty acid/h per g of liver, whereas the controls secreted 7.7 f 1 .Opmol/h per g ( P < 0.02). In addition, the total liver triacylglycerol content was increased significantly. Although the perfusate serum cholesterol concentration did not differ, the total cholesterol content of the liver decreased significantly. Clofibrate feeding for 1 week increased the liver weight from 11.3 & 0.2g to 15.2 & 0.4g, which may account for some of the above results.
The blood [lactate]/[pyruvate] ratio in control perfusions was 8.0, whereas in the perfusions of treated livers it was 4.5. This shift in redox state was also reflected in the perfusate [3-hydroxybutyrate]/[acetoacetate] ratio, which changed from 1.7 in control perfusions to 1.3 in the perfusate of treated livers (P < 0.1). Total ketone bodies also increased owing principally to a doubling in acetoacetate production (P < 0.001).
Livers from treated donors oxidized 6.8 f 0.6% of the [l-14C]oleate free fatty acid to I4CO2 and 2.5 f 0.2% to total ketone bodies, whereas the control livers only oxidized 3.6 f 0.7 % to 14C02 (P < 0.01) and 1.6 f 0.0 % to total ketone bodies (P < 0.02). This increase in oxidation of free fatty acids was accompanied by a decrease in total esterification of free fatty acids from 72.2 f 6.1 % of the 14C-labelled oleate in the controls to 60.6 f 1.9 % in the treated livers. The decrease in esterification was entirely accounted for by a decrease in secretion of esterified fatty acids in very-low-density lipoprotein from 28.0 f 2.6 % to 17.5 f 1.3 % (P < 0.01). Thus many changes are apparent in the livers from animals fed on clofibrate for 1 week, involving shifts in the pattern of lipid and carbohydrate metabolism. Unlike many reports on the immediate actions of clofibrate in disrupted liver preparations, we have been unable to detect significant changes within the first 3 h of exposing the perfused liver to the drug.
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